Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Updates on managing HER2-positive early breast cancer

BGICC 2021

21 - 22 Jan 2021

Published: 16 Feb 2021

Views: 671

Rating:

Save

Dr Javier Cortes - Vall d’Hebron University Hospital, Barcelona, Spain

Dr Javier Cortes speaks to ecancer in an online interview for the virtual BGICC 2021 meeting about updates in managing patients with HER2-positive breast cancer.

Dr Cortes gives updates on newly approved drugs that are improving outcomes, results from recent trials and changes in best practice.

Dr Cortes closes by giving his advice for treating these patients based on recent developments.

Related Videos

ESMO 2024: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2024: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast...

Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German

TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German )

Neo-adjuvant therapy for different cancers in the Philippines

Dr Priscilla Caguioa - St Luke's Medical Center, Manila, Philippines

Neo-adjuvant therapy for different cancers in the Philippines ( Dr Priscilla Caguioa - St Luke's Medical Center, Manila, Philippines )

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+...

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )

Novel antibody-drug conjugates (ADCs) technologies for management of mBC

Prof Hope Rugo - University of California San Francisco, San Francisco, USA

Novel antibody-drug conjugates (ADCs) technologies for management of mBC ( Prof Hope Rugo - University of California San Francisco, San Francisco, USA )

The role of lymph nodes in stage 3 lung cancer

Prof Walter Weder - Privatklinik Bethanien,Zürich, Switzerland

The role of lymph nodes in stage 3 lung cancer ( Prof Walter Weder - Privatklinik Bethanien,Zürich, Switzerland )

The role of multidisciplinary tumour board in managing stage 3 lung cancer

Prof Walter Weder - Privatklinik Bethanien, Zürich, Switzerland

The role of multidisciplinary tumour board in managing stage 3 lung cancer ( Prof Walter Weder - Privatklinik Bethanien, Zürich, Switzerland )

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable...

Dr Ian Krop - Yale Cancer Center, Connecticut, USA

T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable and/or mBC previously treated with T-DM1 ( Dr Ian Krop - Yale Cancer Center, Connecticut, USA )

Systemic anti-cancer performance matrix

Prof Richard Sullivan, Kari Leung and Megan McLeod

Systemic anti-cancer performance matrix ( Prof Richard Sullivan, Kari Leung and Megan McLeod )

More from ecancer